www.arbelebio.com Open in urlscan Pro
103.15.217.83  Public Scan

Form analysis
0 forms found in the DOM

Text Content

   


Toggle navigation
   
 * About Us
   * About ARBELE
   * The Team
 * Focus
   * Our Focus
   * Technology
 * Pipeline
 * News
   * Press
   * Publications
   * Announcements
 * Posts & Notices
   * Tenders
   * Jobs
   * Our Employee Sharing
 * Contact Us


 1. 
 2. 
 3. 
 4. 
 5. 




ABOUT ARBELE



Healing the incurables
Arbele is a biotech and biopharmaceutical company focused on invention of
proprietary immunotherapeutic platforms to accelerate the development of
“first-in-class” antibody-based biologics to treat gastrointestinal cancers, in
particular, stomach, pancreas, colon, bile duct and liver, which remain of high
mortality and with limited treatment options.



Details



Arbele is harnessing this successful approach to develop a potential
first-in-class biologic, ARB-202, to treat refractory colon, gastric and
pancreatic cancers. ARB202 is a humanized antibody that recognizes the specific
tumor antigen CDH17 and the T-cell receptor CD3. It is built on an IgG-scFv
framework and has a two-two tetra valency.



Details



Arbele is developing the next generation of CAR technology, where multiple
components are added to the patient's T cells in addition to the CAR. Arbele is
even exploring the use of a different patient cell type, natural killer or NK
cells, which could be even more powerful and safer than T cells and may not
require the use of the patient's own cells, i.e. “off-the-shelf” products.



Details








OUR PHILOSOPHY





BREAKTHROUGH INNOVATION

Data driven research and proprietary discovery platforms to develop the safest
products with the highest therapeutic potential






HEALTH ENHANCEMENT

To deliver "combination" immunotherapeutics possessing multiple anti-tumor
mechanisms that are curative, or substantially prolong survival and improve
quality of life






SOCIAL IMPACT

Our business is to maximize availability of more effective cancer treatments for
greater global health








Highlights 2016-2022

   
   
 * ARB202 Ph1 trial started at Queen Mary Hospital, Hong Kong 
 * Received TGA approval on ARB202 for Ph1 trials in Australia
 * Received EC approval on ARB202 trials in HK
 * Awarded with HKPC BUD fund 2022
 * Awarded with Clinical Trial Catalyst fund 2022 from HKSTP
 * Winner of BRACE 2021 award of Asian Cancer Research Fund
 * Awarded with ITF PSTS grant 2021 on CDH17 diagnostic assay
 * Awarded with ITF ESS grant 2020 on humanized bispecific antibody
 * HK Most Outstanding Services Award (Biotech industry) 2020
 * Top biotech startup in APAC 2020
 * Pre-IND meeting of ARB202 written notice received from US FDA
 * GLP-Tox and GMP production of ARB202 completed
 * Patent on CDH17 bispecific antibodies and CAR cell therapeutics granted in
   US, AU, IL, CN, and JP (EU and KR pending)
 * Patents filed for TriAx and PARK technology platforms on next-gen
   immunotherapy
 * Joint venture agreement with Avalon Global to develop CAR T cells
   therapeutics
 * Exclusive global license for CDH17 diagnostic marker and molecular target
   patent from HKU
   
 * Research hubs established in Hong Kong, Seattle and Guangzhou








Details









OUR KEY PARTNERS





HKSTP

Arbele is an incubio and LEAP member of the HK Science & Technology Park (since
2016)






HKU

Arbele licenses exclusive global right of the CDH17 patent and collaborating
with the Dept of Pathology and Dept of Surgery at the Queen Mary Hospital,
University of HK






JHL BIOTECH & CHIME BIOLOGICS

strategic alliance and partner on CMC manufacturing of biologic therapeutics 








AVALON GLOBOCARE & WEILL CORNELL MEDICINE

clinical process development and commercialization of CD19 CAR-T product






NOVOTECH CNS

Australia-based clinical CRO to facilitate Arbele First-in-human clinical
studies of ARB202







CHARLES RIVER LAB & CTR DRUG SAFETY EVALUATION & RESEARCH (SIMM)

contracted CRO partners on preclinical and GLP-Tox safety studies









Home

  |  
About Us

  |  
Focus

  |  
Pipeline

  |  
News

  |  
Posts & Notices

  |  
Contact Us

Location:
Seattle | Hong Kong | Greater Bay Area | Sydney    


Copyright 2022
 Arbele
All rights reserved.
 * About Us
   * About ARBELE
   * The Team
 * Focus
   * Our Focus
   * Technology
 * Pipeline
 * News
   * Press
   * Publications
   * Announcements
 * Posts & Notices
   * Tenders
   * Jobs
   * Our Employee Sharing
 * Contact Us

 * MENU
 * About Us
   
   
   ABOUT US
   
    * About ARBELE
    * The Team

 * Focus
   
   
   FOCUS
   
    * Our Focus
    * Technology

 * Pipeline
 * News
   
   
   NEWS
   
    * Press
    * Publications
    * Announcements

 * Posts & Notices
   
   
   POSTS & NOTICES
   
    * Tenders
    * Jobs
    * Our Employee Sharing

 * Contact Us